| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
DSG-PEG targets primary amine groups on proteins, peptides, and other biomolecules. The disuccinimidyl glutarate (DSG) groups react with primary amines (such as the epsilon-amino group of lysine residues) to form stable amide bonds. This allows DSG-PEG to crosslink proteins or to conjugate biomolecules. The PEG spacer provides water solubility and biocompatibility, reducing non-specific interactions. The compound's role as a crosslinking reagent makes it valuable for studying protein-protein interactions and for preparing bioconjugates.
|
|---|---|
| ln Vitro |
In vitro studies of DSG-PEG have focused on its role as a crosslinking reagent for bioconjugation. The compound's reactivity with primary amines has been characterized in various in vitro systems. Its PEG spacer provides water solubility and biocompatibility. These in vitro studies provide foundational data for understanding the compound's utility in protein modification and bioconjugation applications.
|
| ln Vivo |
In vivo studies of DSG-PEG are limited as the compound is primarily used as a research reagent for in vitro bioconjugation. The compound is not intended for administration to living organisms. Its applications are limited to chemical research and bioconjugation. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| Enzyme Assay |
In vitro chemical assays for DSG-PEG involve testing its reactivity with primary amines. The compound's ability to form amide bonds with amines is assessed using standard bioconjugation protocols. High-performance liquid chromatography or mass spectrometry is used to confirm conjugation efficiency. The compound's purity and identity are assessed using analytical chemistry methods. All assays are performed with appropriate controls.
|
| Cell Assay |
In vitro cell-based assays are not applicable for DSG-PEG as the compound is a chemical reagent used for bioconjugation rather than a biological agent. The compound is used to modify proteins and peptides outside of cells. Its reactivity with primary amines is exploited in biochemical applications such as protein crosslinking and labeling. The compound is not intended for cell-based studies as a direct pharmacological agent.
|
| Animal Protocol |
In vivo animal experiments are not applicable for DSG-PEG as the compound is a research reagent used for in vitro bioconjugation rather than a therapeutic agent. The compound is not administered to animals for pharmacological evaluation. Its applications are limited to chemical research and bioconjugation. The compound is not intended for in vivo use.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of DSG-PEG are not applicable as the compound is a research reagent used for in vitro bioconjugation rather than a therapeutic agent. It has a molecular weight of approximately 2000 Da for the PEG component. The compound is stored under appropriate conditions for research use.
|
| Toxicity/Toxicokinetics |
The toxicity profile of DSG-PEG has been evaluated in the context of its use as a research chemical. As a PEG derivative, it is expected to have low toxicity. However, the DSG groups are reactive and should be handled with care. Proper handling procedures including use of personal protective equipment are recommended. The compound is not approved for human therapeutic use and is intended for research purposes only.
|
| References | |
| Additional Infomation |
DSG-PEG (MW 2000, CAS# 308805-39-2) is a polyethylene glycol (PEG) derivative functionalized with disuccinimidyl glutarate (DSG) groups. It is a crosslinking reagent used in bioconjugation and protein modification applications. The PEG spacer provides water solubility and biocompatibility, while the DSG groups react with primary amines to form stable amide bonds. DSG-PEG is used in research applications for crosslinking proteins, peptides, and other biomolecules. It is intended for research use only.
|
| CAS # |
308805-39-2
|
|---|---|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
718.6±55.0 °C at 760 mmHg
|
| Flash Point |
277.4±31.5 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.462
|
| LogP |
16.32
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
